SLC1A5 and breast cancer: In our prior work, we identified the co-expression of three predominant SLCs important in glutamine metabolism—namely, SLC1A5, SLC7A5, and SLC3A2—and that these are significantly overexpressed in aggressive luminal BC subgroups and are associated with poor outcome [7].